What is the current price and short-term outlook for AYA.AX stock?

AYA.AX stock trades at **A$3.20** intraday. Short-term outlook is mixed; Meyka signals a quarterly target of **A$4.36** (up **36.25%**) if commercial adoption accelerates, but watch support at **A$3.12**.

How does Meyka AI grade AYA.AX stock and what does it mean?

Meyka AI rates AYA.AX at **63.44** out of 100 (Grade B, HOLD). The grade balances growth potential, sector comparison and financial metrics. Grades are model outputs and not financial advice.

What are the main risks for AYA.AX stock investors?

Main risks include regulatory approval timing, slow hospital procurement cycles, ongoing negative earnings, and limited trading liquidity. Low debt helps the cash runway but execution must improve for valuation to reset.

What price targets should investors watch for AYA.AX stock?

Meyka AI's near-term targets: **A$3.05** monthly, **A$4.36** quarterly, and **A$7.41** for 12 months. Use these as scenario markers, not guaranteed outcomes.

AU Stocks

AYA.AX Artrya Limited ASX falls 5.04% to A$3.20 intraday: AI diagnosis growth under watch

ByHuzaifa Zahoor March 14, 2026March 14, 2026

Artrya Limited (AYA.AX) is trading A$3.20 intraday on the ASX, down 5.04% on volume of 274,842 shares. The move follows mixed trading since the open at A$3.35, with a day low of A$3.12 and a day high of A$3.35. We track AYA.AX stock as part of the AI healthcare cohort. This note uses real-time quote details, sector context and Meyka AI-powered market analysis platform signals to assess near-term catalysts and upside targets for investors in Australia (AUD) markets.